CN112062744A - Terpene phenolic compound ZKYY-057 and preparation method and application thereof - Google Patents
Terpene phenolic compound ZKYY-057 and preparation method and application thereof Download PDFInfo
- Publication number
- CN112062744A CN112062744A CN202011176030.XA CN202011176030A CN112062744A CN 112062744 A CN112062744 A CN 112062744A CN 202011176030 A CN202011176030 A CN 202011176030A CN 112062744 A CN112062744 A CN 112062744A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- column chromatography
- silica gel
- gel column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- -1 Terpene phenolic compound Chemical class 0.000 title claims abstract description 12
- 235000007586 terpenes Nutrition 0.000 title claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 72
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 20
- 201000005202 lung cancer Diseases 0.000 claims abstract description 20
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 20
- 201000007270 liver cancer Diseases 0.000 claims abstract description 13
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 13
- 235000011624 Agave sisalana Nutrition 0.000 claims abstract description 10
- 244000198134 Agave sisalana Species 0.000 claims abstract description 10
- 230000004663 cell proliferation Effects 0.000 claims abstract description 10
- 239000000287 crude extract Substances 0.000 claims abstract description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- 238000010828 elution Methods 0.000 claims description 23
- 238000010898 silica gel chromatography Methods 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 238000000926 separation method Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 229940041181 antineoplastic drug Drugs 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000004007 reversed phase HPLC Methods 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000010829 isocratic elution Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 72
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 48
- 230000004083 survival effect Effects 0.000 description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 15
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 14
- 238000012258 culturing Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 9
- 230000003698 anagen phase Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 238000012935 Averaging Methods 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 230000005757 colony formation Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a terpene phenolic compound ZKYY-057, a preparation method and application thereof, wherein the compound has a structure shown in a formula I:
the compound shown in the formula I can be obtained by extracting the inflorescence of the hemp plant to obtain a crude extract, and then separating the crude extract, and cell experiments show that the compound shown in the formula I has better anti-tumor cell proliferation activity, and particularly has obvious effect of inhibiting cell proliferation in liver cancer cells and lung cancer cells.
Description
Technical Field
The invention relates to the technical field of biological medicines, and particularly relates to a terpene phenolic compound ZKYY-057 and a preparation method and application thereof.
Background
The hemp plant is a plant with a complex chemical type, mainly because the hemp plant contains many natural chemical components. By 1980, there were 432 species of compounds isolated from hemp plants, increasing to 483 species by 1995 and 490 species by 2005. The biological activity of cannabis is well known and with the discovery of receptors, there is an opportunity to explore physiologically active compounds in cannabis as a source of new therapeutic agents. There are also an increasing number of patients suffering from severe diseases such as cancer who seek natural drugs as an alternative or complementary therapy, and there is a continuing need for new treatments for cancer or other symptoms.
The incidence rate of cancer is gradually high due to different living habits, environmental factors and other reasons, the malignant tumor is found to be a disease which is difficult to cure once being found in an advanced stage, and the cancer incidence rate is high and the cancer is difficult to cure at present, so the method has important significance for screening active ingredients in the hemp plants.
Disclosure of Invention
In view of the above, the invention provides an application of a terpene phenolic compound ZKYY-057 with a molecular formula of C21H31O3And the molecular weight is 330.47, and the compound has good anti-tumor cell proliferation activity.
The invention provides a terpene phenolic compound ZKYY-057, which has a structure shown in a formula I:
the invention also provides a preparation method of the compound shown in the formula I, which comprises the following steps:
(1) sequentially performing carbon dioxide supercritical extraction and ethanol extraction on the hemp plant inflorescence to obtain a crude extract;
(2) dissolving the obtained crude extract, and separating by normal phase silica gel column chromatography, macroporous adsorbent resin column chromatography, primary medium pressure normal phase silica gel column chromatography, secondary medium pressure normal phase silica gel column chromatography, tertiary medium pressure normal phase silica gel column chromatography, and high pressure reverse phase HPLC chromatography to obtain compound shown in formula I.
Preferably, the method of preparation comprises any one or more of the following features: firstly, the supercritical carbon dioxide extraction conditions are as follows: pExtraction kettle＝20-30MPa，TExtraction kettle＝35-60℃；PSeparation kettle I＝8-11MPa，TSeparation kettle I＝35-65℃；PSeparation kettle II＝3-6MPa，TSeparation kettle II30-40 ℃; secondly, the usage amount of ethanol in the ethanol extraction is 15-25% of the weight of the hemp plant inflorescence, and the extraction time is 30-60 min; thirdly, fully dissolving the crude extract by using petroleum ether; fourthly, the normal phase silica gel column chromatography is carried out with n-hexane/ethyl acetate 98:2 as an eluent for isocratic elution; fifthly, performing gradient elution on the macroporous adsorption resin column by adopting a D101 macroporous adsorption resin column and using 30-100% ethanol/water as an eluent; sixthly, performing gradient elution on the first-stage medium-pressure normal-phase silica gel column chromatography by using dichloromethane/ethyl acetate as an eluent; seventhly, performing gradient elution on the secondary medium-pressure normal-phase silica gel column chromatography by using n-hexane/diethyl ether as an eluent; eighthly, carrying out gradient elution on the three-stage medium-pressure normal-phase silica gel column chromatography by using n-hexane/diethyl ether as an eluent; and ninthly, carrying out gradient elution by using acetonitrile/water solution as an eluent by the high-pressure reversed-phase HPLC chromatography.
The invention also provides application of the compound shown in the formula I in preparing a tumor cell proliferation inhibitor.
Correspondingly, the invention provides a tumor cell proliferation inhibitor drug which is characterized by comprising an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient comprises a compound shown in a formula I.
The invention also provides application of the compound shown in the formula I in preparing a medicament for treating tumor diseases.
Correspondingly, the invention provides an anti-tumor medicament which comprises an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient comprises a compound shown in a formula I.
Preferably, the tumor disease is liver cancer or lung cancer.
Preferably, the medicament comprises an effective dose of the compound shown in the formula I, and the effective dose is 660ng per dose.
Preferably, the medicine is an oral preparation or an injection preparation, and the oral preparation is one of dripping pills, tablets, capsules, granules or oral liquid; the injection preparation is selected from injection or powder injection.
The invention has the beneficial effects that: the terpene phenol compound ZKYY-057 shown in the formula I is high in purity, good in stability and good in biological activity, and the compound shown in the formula I has good anti-tumor cell proliferation activity through cell experiments, and particularly has an obvious effect of inhibiting cell proliferation in liver cancer cells and lung cancer cells.
Drawings
FIG. 1 is a graph showing the effect of compounds of formula I on the survival rate of human hepatoma cells (HepG 2);
FIG. 2 shows the effect of compounds of formula I on the survival of human lung cancer cells (A549);
FIG. 3 shows the effect of compounds of formula I on the survival of human hepatoma cells (HepG 2);
FIG. 4 shows the effect of compounds of formula I on the survival of human lung cancer cells (A549);
FIG. 5 shows a microscopic image of cell colonies after treatment of human hepatoma cells (HepG2) with a compound of formula I;
FIG. 6 shows the effect of compounds of formula I on the colony formation of human hepatoma cells (HepG 2);
FIG. 7 shows a microscopic image of a cell colony obtained after treatment of human lung cancer cells (A549) with a compound of formula I;
FIG. 8 shows the effect of compounds of formula I on colony formation of human lung cancer cells (A549);
FIG. 9 shows the effect of compounds of formula I on the mobility of human hepatoma cells (HepG 2);
FIG. 10 shows the effect of compounds of formula I on the mobility of human lung cancer cells (A549);
FIG. 11 shows compounds of formula I1H-NMR spectrum;
FIG. 12 shows a compound of formula I13A C-NMR spectrum;
figure 13 shows the HSQC spectrum of the compound shown as formula I.
Detailed Description
To explain technical contents, structural features, and objects and effects of the technical solutions in detail, the following detailed description is given with reference to the accompanying drawings in conjunction with the embodiments.
The invention provides a terpene phenolic compound ZKYY-057, which has a structure shown in a formula I:
example 1
The preparation method of the terpene phenolic compound ZKYY-057 shown in the formula I comprises the following steps:
(1) taking a hemp plant inflorescence as a raw material, crushing 500g of a dried sample, and performing supercritical extraction by using carbon dioxide. The extraction conditions were: pExtraction kettle＝30MPa，TExtraction kettle＝45℃；PSeparation kettle I＝8MPa，TSeparation kettle I＝45℃；PSeparation kettle II＝6MPa，TSeparation kettle IIThe temperature is 35 ℃; adding 20 wt% ethanol as carrier, and extracting for 45 min. Extracting to obtain 101.031g of crude extract.
(2) And (2) fully dissolving 50g of crude extract by using petroleum ether, performing normal-phase silica gel column chromatography by using a Changzhou trite medium-pressure rapid preparation chromatograph, performing gradient elution by using n-hexane/ethyl acetate 98:2 and the like until the peak value of the sixth peak of online detection is lower than 100mAU and the flow rate is 80mL/min, analyzing by using thin-layer chromatography, and combining the sixth peaks of online detection maps to obtain a first-stage component containing the target compound. And (3) taking 7.8g of first-grade component, further separating by using D101 macroporous adsorption resin column chromatography, carrying out gradient elution by using 30-100% ethanol/water in an elution system, and regulating the flow rate until the eluent flows down in a strand. And (4) carrying out thin-layer chromatography analysis, and combining the elution parts of 45% ethanol solution to obtain a secondary component containing the target compound. And taking 1.62g of the secondary component, and further performing medium-pressure normal-phase silica gel column chromatography separation, wherein an elution system is a dichloromethane/ethyl acetate system for gradient elution, and the elution is carried out until the peak value of the eighth peak detected on line is lower than 50mAU, and the flow rate is 15 mL/min. And (3) carrying out thin-layer chromatography analysis, combining the second peaks of the online detection spectra to obtain a third-stage component containing the target compound, taking 0.313g of the third-stage component, further carrying out medium-pressure normal-phase silica gel column chromatography separation, carrying out gradient elution by using n-hexane/diethyl ether in an elution system until the peak value of the thirteenth peak detected online is lower than 30mAU, and carrying out flow rate of 15 mL/min. And (3) carrying out thin-layer chromatography analysis, combining the ninth peak of the online detection spectrum to obtain a fourth-stage component containing the target compound, taking 0.064g of the fourth-stage component, further carrying out chromatography separation by adopting medium-pressure normal-phase silica gel, carrying out gradient elution by using n-hexane/diethyl ether in an elution system until the peak value of the second peak of the online detection is lower than 10mAU, and carrying out flow rate of 10 mL/min. Performing thin-layer chromatography, combining the first peaks of the online detection maps to obtain a five-level component containing the target compound, taking 0.048g of the five-level component, further performing high-pressure reverse phase preparation by HPLC (high performance liquid chromatography), performing gradient elution by acetonitrile/water and the like in an elution system, wherein the peak-out time of the target compound is 18.29min, the detection wavelength is 228nm, and finally obtaining 32mg of the target compound;
(3) analyzing the structure of the target compound, finally determining the hydrogen spectrum and carbon spectrum information of the data through a nuclear magnetic resonance spectrogram (figures 11-12), comprehensively identifying the structure of the compound as shown in formula I by combining the hydrogen spectrum and carbon spectrum information with the correlation literature data Isolation and pharmaceutical Evaluation of Minor Cannabinoids from High-potential Cannabis sativa, wherein the nuclear magnetic resonance hydrogen spectrum and carbon spectrum data of the target compound are as follows:
1H NMR(600MHz,MeOD)6.74–6.70(m,1H),6.16(d,J＝1.7Hz,1H),6.09(d,J＝1.7Hz,1H),4.02(d,J＝4.5Hz,1H),3.05(d,J＝10.6Hz,1H),2.40(t,J＝7.6Hz,2H),1.98(dt,J＝13.3,1.8Hz,1H),1.87–1.81(m,1H),1.81–1.77(m,3H),1.58–1.51(m,3H),1.38(s,3H),1.36–1.27(m,4H),1.05(s,3H),0.90(t,J＝7.2Hz,3H).
13C NMR(151MHz,MeOD)155.85,154.49,142.14,133.46,128.28,108.43,107.93,106.96,76.27,67.67,47.91,47.77,47.63,47.48,47.34,40.45,35.21,34.87,34.54,31.24,30.64,26.46,22.21,19.63,18.40,13.04.
example 2
Identification of antitumor activity of terpene phenolic compound ZKYY-057 shown in formula I
Medicine preparation: the terpene phenolic compound ZKYY-057 of formula I prepared in example 1.
(1) MTT colorimetric method for detecting influence of compound shown as formula I on tumor cell survival performance
Taking human liver cancer cells (HepG2) in a logarithmic growth phase, using a DMEM culture medium, adjusting the cell concentration to 7000 cells, inoculating 100 mu L of DMEM culture medium in each well into a 96-well plate, culturing in an incubator until the cells adhere to the wall, using 100 mu L of DMSO as a solvent to respectively prepare compound solutions shown in formula I with the concentrations of 20ug/ml and 40ug/ml, respectively adding the prepared compounds shown in formula I with the concentrations of 20ug/ml and 40ug/ml into experimental groups for treatment, adding 100 mu L of DMSO into blank groups, and acting for 24 hours under the culture medium; detecting cell survival rate with MTT reagent by using 20ug/ml antitumor drug cisplatin (DDP) as control, repeating for 3 times, and averaging;
as shown in FIG. 1, the survival rate of the human liver cancer cell (HepG2) is lower with the increase of the concentration, i.e. the inhibition effect of the compound ZKYY-057 shown in the formula I on the survival performance of the human liver cancer cell (HepG2) is stronger; when the concentration is 40ug/ml, the inhibition effect is stronger than that of the antitumor drug DPP with the dosage of 20 ug/ml.
Taking human lung cancer cells (A549) in logarithmic growth phase, adjusting the number of the cells to 7000 by using a DMEM medium, inoculating 100 mu L of the DMEM medium in each well into a 96-well plate, culturing the 96-well plate in an incubator until the cells adhere to the wall, respectively preparing compound solutions shown in the formula I with the concentrations of 20ug/ml and 40ug/ml by using 100 mu L of DMSO as solvents, respectively adding the prepared compounds shown in the formula I with the concentrations of 20ug/ml and 40ug/ml into an experimental group for treatment, adding 100 mu L of DMSO into a blank group, and acting for 24 hours in the culture medium; detecting cell survival rate with MTT reagent by using 20ug/ml antitumor drug cisplatin (DDP) as control, repeating for 3 times, and averaging;
as shown in fig. 2, the survival rate of the human lung cancer cell (a549) is lower with the increase of the concentration, i.e., the inhibition effect of the compound ZKYY-057 shown in formula I on the survival of the human lung cancer cell (a549) is stronger; when the concentration is 40ug/ml, the inhibition effect is stronger than that of the antineoplastic drug cisplatin (DDP) with the dosage of 20 ug/ml.
(2) CKK8 cell proliferation toxicity detection method for detecting influence of compound shown in formula I on tumor cell survival performance
Taking human liver cancer cells (HepG2) in a logarithmic growth phase, adjusting the cell concentration to 7000 cells by using a DMEM culture medium, inoculating 100 mu L of the DMEM culture medium into each well of a 96-well plate, culturing in an incubator at 37 ℃ until the cells adhere to the wall, respectively preparing compound solutions shown in the formula I with the concentrations of 20ug/ml and 40ug/ml by using 100 mu L of DMSO as a solvent, respectively adding the prepared compounds shown in the formula I with the concentrations of 20ug/ml and 40ug/ml into experimental groups for treatment, adding 100 mu L of DMSO into blank groups, and acting for 24 hours in the culture medium; detecting cell survival rate with CCK8 kit with 20ug/ml antitumor drug cisplatin (DDP) as control, repeating for 3 times, and averaging;
as shown in FIG. 3, the survival rate of human liver cancer cells (HepG2) is lower with the increase of concentration, i.e. the inhibiting effect of the compound shown in formula I on the survival of human liver cancer cells (HepG2) is stronger; when the concentration is 40ug/ml, the inhibition effect is basically equivalent to that of the antitumor drug cisplatin (DDP) with the dosage of 20 ug/ml.
Taking human lung cancer cells (A549) in logarithmic growth phase, adjusting the number of the cells to 7000 by using a DMEM medium, inoculating 100 mu L of the DMEM medium in each well into a 96-well plate, culturing the 96-well plate in an incubator until the cells adhere to the wall, respectively preparing compound solutions shown in the formula I with the concentrations of 20ug/ml and 40ug/ml by using 100 mu L of DMSO as solvents, respectively adding the prepared compounds shown in the formula I with the concentrations of 20ug/ml and 40ug/ml into an experimental group for treatment, adding 100 mu L of DMSO into a blank group, and acting for 24 hours in the culture medium; detecting cell survival rate with CCK8 kit with 20ug/ml antitumor drug cisplatin (DDP) as control, repeating for 3 times, and averaging;
as shown in fig. 4, the survival rate of human lung cancer cell (a549) is lower with the increase of the concentration, i.e., the compound of formula I has stronger inhibition effect on the survival of human lung cancer cell (a 549); when the concentration is 40ug/ml, the inhibition effect is stronger than that of the antineoplastic drug cisplatin (DDP) with the dosage of 20 ug/ml.
(3) Cell clone colony forming method for detecting influence of compound shown as formula I on proliferation performance of tumor cells
Taking human liver cancer cells (HepG2) in a logarithmic growth phase, digesting the cells into single cells, inoculating the single cells to a 6-well plate, adding 350 cells in each well, adding a human DMEM culture medium 3ML, culturing the cells to an adherent position in an incubator, using 100 mu L DMSO as a solvent to respectively prepare compound solutions shown in the formula I with the concentrations of 20ug/ML and 40ug/ML, respectively adding the prepared compounds shown in the formula I with the concentrations of 20ug/ML and 40ug/ML into an experimental group, adding 100 mu L DMSO into a blank group, replacing fresh culture medium and medicament every 2-3 days, and continuously culturing for one week until macroscopic clones are formed; after each well is treated, a proper amount of 0.1% crystal violet is added for staining, then the staining solution is slowly washed away by running water, the cells are dried in the air, the clone number of the cells is counted, a picture is taken under a microscope (figure 5), and the cell colony forming rate is calculated. As shown in FIG. 6, the lower the colony formation rate of human hepatoma cells (HepG2) with increasing concentration, i.e., the stronger the inhibitory effect of the compound of formula I on the proliferation of human hepatoma cells (HepG 2).
Taking human lung cancer cells (A549) in a logarithmic growth phase, digesting the cells into single cells, inoculating the single cells to a 6-well plate, adding 350 cells in each well, adding a human DMEM culture medium 3ML, culturing the cells to adhere to the wall in an incubator, respectively preparing compound solutions shown in formula I with the concentrations of 20ug/ML and 40ug/ML by taking 100 mu L of DMSO as a solvent, respectively adding the prepared compounds shown in formula I with the concentrations of 20ug/ML and 40ug/ML into an experimental group, respectively treating the experimental group, adding 100 mu L of DMSO into a blank group, replacing fresh culture medium and medicament every 2-3 days, and continuously culturing for one week until macroscopic clones are formed; after each well is treated, a proper amount of 0.1% crystal violet is added for staining, then the staining solution is slowly washed away by running water, the cells are dried in the air, the clone number of the cells is counted, a picture is taken under a microscope (figure 7), and the cell colony forming rate is calculated. As shown in fig. 8, the lower the colony formation rate of human lung cancer cell (a549) with the increase in concentration, i.e., the stronger the inhibitory effect of the compound of formula I on the proliferation of human lung cancer cell (a 549).
(4) Detecting the influence of the compound shown as the formula I on the migration performance of tumor cells
Taking tumor cells in logarithmic growth phase as human liver cancer cells (HepG2), adjusting the cell concentration to 70000 cells/ML by using a DMEM culture medium, inoculating 2ML of DMEM culture medium in each hole into a 12-hole plate, culturing until the DMEM culture medium is fully paved at the bottom of the 12-hole plate, and drawing a line from top to bottom by using culture holes of a sterile gun head; preparing compound solutions shown in the formula I with the concentration of 20ug/ml and 40ug/ml by taking 100 mu L of DMSO as a solvent, adding the prepared compounds shown in the formula I with the concentration of 20ug/ml and 40ug/ml into an experimental group for treatment, adding 100 mu L of DMSO into a blank group, taking different time points within 0-24 h for observation and photographing, and counting the cell migration condition by calculating the area of a cell-free area in a scratch area.
As shown in FIG. 9, the compound of formula I can inhibit the migration ability of human liver cancer cells (HepG2), and the tumor cell migration rate decreases with increasing concentration, showing a decreasing relationship.
Taking tumor cells in logarithmic growth phase as human lung cancer cells (A549), adjusting the cell concentration to 70000 cells/ML by using a DMEM medium, inoculating 2ML of DMEM medium in each hole into a 12-hole plate, culturing until the DMEM medium is fully paved at the bottom of the 12-hole plate, and drawing a line from top to bottom by using culture holes of a sterile gun head; preparing compound solutions shown in the formula I with the concentration of 20ug/ml and 40ug/ml by taking 100 mu L of DMSO as a solvent, adding the prepared compounds shown in the formula I with the concentration of 20ug/ml and 40ug/ml into an experimental group for treatment, adding 100 mu L of DMSO into a blank group, taking different time points within 0-24 h for observation and photographing, and counting the cell migration condition by calculating the area of a cell-free area in a scratch area.
The results are shown in fig. 10, the compound shown in formula I can inhibit the migration ability of human lung cancer cells (a549), and the tumor cell migration rate decreases with increasing concentration, showing a decreasing relationship.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or terminal that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or terminal. Without further limitation, an element defined by the phrases "comprising … …" or "comprising … …" does not exclude the presence of additional elements in a process, method, article, or terminal that comprises the element. Further, herein, "greater than," "less than," "more than," and the like are understood to exclude the present numbers; the terms "above", "below", "within" and the like are to be understood as including the number.
Although the embodiments have been described, once the basic inventive concept is obtained, other variations and modifications of these embodiments can be made by those skilled in the art, so that the above embodiments are only examples of the present invention, and not intended to limit the scope of the present invention, and all equivalent structures or equivalent processes using the contents of the present specification and drawings, or any other related technical fields, which are directly or indirectly applied thereto, are included in the scope of the present invention.
Claims (10)
1. A terpene phenolic compound ZKYY-057 has a structure shown in formula I:
2. a process for the preparation of a compound of formula I according to claim 1, comprising the steps of:
(1) sequentially performing carbon dioxide supercritical extraction and ethanol extraction on the hemp plant inflorescence to obtain a crude extract;
(2) dissolving the obtained crude extract, and separating by normal phase silica gel column chromatography, macroporous adsorbent resin column chromatography, primary medium pressure normal phase silica gel column chromatography, secondary medium pressure normal phase silica gel column chromatography, tertiary medium pressure normal phase silica gel column chromatography, and high pressure reverse phase HPLC chromatography to obtain compound shown in formula I.
3. The method of claim 2, comprising any one or more of the following features: firstly, the supercritical carbon dioxide extraction conditions are as follows: pExtraction kettle＝20-30MPa，TExtraction kettle＝35-60℃；PSeparation kettle I＝8-11MPa，TSeparation kettle I＝35-65℃；PSeparation kettle II＝3-6MPa，TSeparation kettle II30-40 ℃; secondly, the usage amount of ethanol in the ethanol extraction is 15-25% of the weight of the hemp plant inflorescence, and the extraction time is 30-60 min; thirdly, fully dissolving the crude extract by using petroleum ether; fourthly, the normal phase silica gel column chromatography is carried out with n-hexane/ethyl acetate 98:2 as an eluent for isocratic elution; fifthly, performing gradient elution on the macroporous adsorption resin column by adopting a D101 macroporous adsorption resin column and using 30-100% ethanol/water as an eluent; sixthly, performing gradient elution on the first-stage medium-pressure normal-phase silica gel column chromatography by using dichloromethane/ethyl acetate as an eluent; seventhly, performing gradient elution on the secondary medium-pressure normal-phase silica gel column chromatography by using n-hexane/diethyl ether as an eluent; eighthly, carrying out gradient elution on the three-stage medium-pressure normal-phase silica gel column chromatography by using n-hexane/diethyl ether as an eluent; and ninthly, carrying out gradient elution by using acetonitrile/water solution as an eluent by the high-pressure reversed-phase HPLC chromatography.
4. The application of the compound shown in the formula I in preparing a tumor cell proliferation inhibitor.
5. The tumor cell proliferation inhibitor medicine is characterized by comprising an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient comprises a compound shown in a formula I.
6. The use of a compound of formula I in the manufacture of a medicament for the treatment of a neoplastic disease.
7. An antitumor drug is characterized by comprising an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient comprises a compound shown as a formula I.
8. The use according to claim 4 or 6, wherein the neoplastic disease is liver cancer or lung cancer.
9. Antineoplastic drug according to claim 5 or 8, characterized in that said drug comprises an effective dose of compound represented by formula I, preferably an effective dose of 660 ng/dose.
10. The antitumor drug as claimed in claim 5 or 8, wherein the drug is an oral preparation or an injection preparation, and the oral preparation is one selected from dripping pills, tablets, capsules, granules or oral liquid; the injection preparation is selected from injection or powder injection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010135238.0A CN111233814A (en) | 2020-03-02 | 2020-03-02 | Terpene phenolic compound ZKYY-057 and preparation method and application thereof |
| CN2020101352380 | 2020-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112062744A true CN112062744A (en) | 2020-12-11 |
Family
ID=70873273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010135238.0A Pending CN111233814A (en) | 2020-03-02 | 2020-03-02 | Terpene phenolic compound ZKYY-057 and preparation method and application thereof |
| CN202011176030.XA Pending CN112062744A (en) | 2020-03-02 | 2020-10-29 | Terpene phenolic compound ZKYY-057 and preparation method and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010135238.0A Pending CN111233814A (en) | 2020-03-02 | 2020-03-02 | Terpene phenolic compound ZKYY-057 and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111233814A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111574531A (en) * | 2020-05-15 | 2020-08-25 | 福建省中科生物股份有限公司 | Terpene phenolic compound NO85, and preparation method and application thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111560001A (en) * | 2020-05-15 | 2020-08-21 | 福建省中科生物股份有限公司 | Phenolic compound NO84, and preparation method and application thereof |
| CN111548332A (en) * | 2020-05-15 | 2020-08-18 | 福建省中科生物股份有限公司 | Terpene phenolic compound NO95, and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1452485A (en) * | 2000-05-17 | 2003-10-29 | 劳伦斯·雷彻 | Cannabinoid drugs |
| US20140221469A1 (en) * | 2011-09-12 | 2014-08-07 | Otsuka Pharmaceutical Co., Ltd. | Phytocannabinoids for use in the treatment of cancer |
-
2020
- 2020-03-02 CN CN202010135238.0A patent/CN111233814A/en active Pending
- 2020-10-29 CN CN202011176030.XA patent/CN112062744A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1452485A (en) * | 2000-05-17 | 2003-10-29 | 劳伦斯·雷彻 | Cannabinoid drugs |
| US20140221469A1 (en) * | 2011-09-12 | 2014-08-07 | Otsuka Pharmaceutical Co., Ltd. | Phytocannabinoids for use in the treatment of cancer |
Non-Patent Citations (4)
| Title |
|---|
| AFEEF S. HUSNI 等: "Evaluation of phytocannabinoids from high-potency Cannabis sativa using in vitro bioassays to determine structure–activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2", 《MED CHEM RES》 * |
| M. BINDER等: "Microbial Transformation of Cannabinoids. Part 2*; A Screening of Different Microorganisms", 《EUROPEAN J. APPL. MICROBIOL. BIOTECHNOL.》 * |
| 朱晓琴等: "大麻受体激动剂对肺癌A549细胞凋亡和增殖的影响", 《华中科技大学学报（医学版）》 * |
| 韩宏星等: "天然二萜酚类化合物研究进展", 《天然产物研究与开发》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111574531A (en) * | 2020-05-15 | 2020-08-25 | 福建省中科生物股份有限公司 | Terpene phenolic compound NO85, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111233814A (en) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112190577B (en) | Application and preparation method of phenolic compound ZKYY-041 | |
| CN112194572B (en) | Phenolic compound ZKYY-037 and preparation method and application thereof | |
| CN112062744A (en) | Terpene phenolic compound ZKYY-057 and preparation method and application thereof | |
| Yang et al. | Isolation and identification of a tribenzylisoquinoline alkaloid from Nelumbo nucifera Gaertn, a novel potential smooth muscle relaxant | |
| CN111548332A (en) | Terpene phenolic compound NO95, and preparation method and application thereof | |
| CN112807301A (en) | Application of Cannabicol extracted from hemp plant in preparing antitumor drug | |
| CN111560001A (en) | Phenolic compound NO84, and preparation method and application thereof | |
| CN111228246A (en) | Application and preparation method of terpene phenol | |
| CN111574531A (en) | Terpene phenolic compound NO85, and preparation method and application thereof | |
| CN111377994A (en) | Seven withanolides compounds from cape gooseberry and preparation method and application thereof | |
| CN109608419B (en) | Diaryl heptane compounds extracted from exocarpium Juglandis Immaturum, and preparation method and application thereof | |
| CN111184710A (en) | Application and preparation method of cyclic phenol | |
| CN107226820B (en) | A kind of trichophytin J with antitumor action and preparation method thereof and purposes | |
| CN111454153B (en) | Five ent-tisane diterpene compounds from euphorbia humifusa and preparation method and application thereof | |
| CN112079811A (en) | Phenolic compound ZKYY-013 and preparation method and application thereof | |
| CN109734696B (en) | Novel diepoxy lignan compound and preparation method thereof | |
| CN111777512A (en) | Five diterpenoid compounds derived from euphorbia tirucalli as well as preparation method and application thereof | |
| CN112516134B (en) | Application of hydroxyl-containing compound in preparation of medicines | |
| CN112300185B (en) | Alkaloid compound with reduced hepatotoxicity, and preparation method and application thereof | |
| CN110638822A (en) | Albizzia julibrissin glycoside compound for promoting endothelial cell proliferation and application thereof | |
| CN109438195B (en) | Novel naphthalene compound and preparation method thereof | |
| CN114805382B (en) | Sesquiterpene chromone compound, separation thereof and application thereof in preparation of pancreatic cancer resisting drugs | |
| CN104324043B (en) | A kind of purposes of cardiac glycoside compound | |
| CN109575089B (en) | Acylated glucose compounds, pharmaceutical composition, preparation method and application thereof | |
| CN109879885B (en) | Novel compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201211 |
|
| RJ01 | Rejection of invention patent application after publication |